share_log

BioNTech | 6-K: BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer

BioNTech | 6-K: BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer

BioNTech | 6-K:BioNTech 和DualityBio获得FDA对前列腺癌抗体药物偶联候选物BNT324/DB-1311的快速通道认证
美股SEC公告 ·  06/24 08:10
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息